Tag: rivaroxaban

rivaroxaban xarelto

Rivaroxaban recommended by NICE for peripheral and coronary artery disease patients

The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draft final appraisal determination recommending the use of...

PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in...

Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at...

Rivaroxaban gets FDA approval for treatment in CAD or PAD

Rivaroxaban, brand name Xarelto (Janssen), has received approval by the US Food and Drug Administration (FDA) to reduce the risk of major cardiovascular (CV)...
Xarelto

Bayer announces new licensed indication for use of Xarelto in patients...

Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or...
Xarelto

ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...

The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...

COMPASS study of Janssen’s rivaroxaban to end early for efficacy

The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...

Two new real-world studies confirm positive efficacy and safety profile of...

Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...